

Colleagues,

Please find below the National Notifiable Diseases Surveillance System (NNDSS) Modernization Initiative (NMI) Technical Assistance (TA) Coordination Team Update for August 14, 2015. These e-mail updates are a collaboration among the Centers for Disease Control and Prevention (CDC), Council of State and Territorial Epidemiologists (CSTE), and the Association of Public Health Laboratories (APHL) and are sent biweekly in an effort to keep reporting jurisdictions and other partners and stakeholders updated on the progress of NMI.

For more information on NMI, please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>. If you have questions not answered in the FAQs, please send them to [edx@cdc.gov](mailto:edx@cdc.gov).

## **NNDSS Modernization Initiative Biweekly Update**

**August 14, 2015**

### **Message Mapping Guide Development Updates**

- **Message Mapping Guide (MMG) Status Updates:**
  - **Arboviral MMG (Requirements Analysis):**
    - Requirements analysis is approximately 75% complete.
    - The CDC Surveillance Operations Team (SOT) and Message and Vocabulary (M&V) Team are reviewing the feedback received from the program regarding the complete list of data elements needed for the guide.
  - **Varicella MMG (Requirements Analysis):**
    - Requirements analysis is approximately 80% complete.
    - The CDC program approved the draft MMG timeline on 7/27/15.
    - The CDC program received the first draft of the data element mappings from the SOT on 7/30/15.
  - **Mumps and Pertussis MMGs ([Stage I—Draft Phase](#)):**
    - The CDC program approved the test-ready Mumps and Pertussis MMGs, Test Scenarios, and annotated case surveillance worksheets on 7/16/15. SOT is working on updates to the draft test scenarios and test messages.
  - **Congenital Syphilis and STD MMGs ([Stage II—Pilot Test-ready Draft Phase](#))**
    - The MMG Development Team posted pilot test-ready versions of the STD and Congenital Syphilis MMGs and their artifacts to the Draft MMG Web Site.
  - **Generic v2 and Hepatitis MMGs ([Stage II—Pilot Test-ready Draft Phase](#))**
    - The MMG Development Team posted pilot test-ready versions of the Generic v2 and Hepatitis MMGs and their artifacts to the Draft MMG Web Site.
  - No guides are in [Stage III—Final MMG Phase](#) at this time.

### **Message Validation, Processing, and Provisioning System Updates**

- The Message Validation, Processing, and Provisioning System (MVPS) developer delivered the revised message processing functionality for Generic v2, STD, and Hepatitis to CDC on 7/2/15.
  - The installation script for the code had issues and the developer resent it on 7/6/15. The MVPS Team installed the code and retested it to confirm resolution of defects reported to the MVPS developer on 6/19/15.

- During technical acceptance testing, the MVPS Team identified defects with the dashboard security functionality where programs could not access errors, warnings, or the raw HL7 message. The MVPS developer delivered a patch on 7/31/15 to resolve these defects, and the MVPS Team is applying the patch.
- The MVPS Team received the SQL Server Integration Services (SSIS) package needed to move forward with the cutover from the single-server production environment to the multi-server environment for the current production system supporting PHLIP Vaccine Preventable Disease (VPD) messages, which occurred on 7/13/15.
  - The next step after the single-server/multi-server production cutover is to move the new message processing code to the test environment to prepare for user acceptance testing (UAT).
  - The MVPS Team will make the code available to CDC programs and NMI pilot jurisdictions in support of independent validation testing, a component of UAT.
- User acceptance testing of the MVPS Dashboard and message processing functionality by the NMI pilot jurisdictions and CDC programs is being planned.
  - The MVPS Team held training for the CDC programs participating in MVPS UAT on 7/29/15 and 7/30/15 and for the pilot jurisdictions participating in UAT on 8/3/15. Participants learned how to use the MVPS Dashboard, what is expected of them during UAT, and how to conduct testing and report findings.
  - For jurisdictions to be able to access the UAT environment through CDC Secure Access Management Services (SAMS), the MVPS Team is awaiting CDC Office of the Chief Information Security Officer approval. Jurisdiction UAT will be delayed until MVPS has approval to proceed.
  - Other trainings for CDC programs and jurisdictions focused on end-to-end and regression testing are targeted for the end of August 2015.
- The MVPS Team continues to work on finalizing the data provisioning requirements and data dictionary mapping for Generic v2, Hepatitis, and STD in conjunction with SOT and the M&V Team.
  - The MVPS Team delivered the Generic v2 requirements to the MVPS developer on 6/4/15.
  - The MVPS Team met with the CDC programs to discuss the Generic v2, Hepatitis (7/23/15), and STD (8/4/15) data provisioning design and approach.
  - The MVPS Team delivered the data provisioning requirements to the MVPS developer for Hepatitis on 7/31/15 and expects to deliver requirements for STD by mid-August 2015.
- The MVPS team is working on the requirements for the upcoming Congenital Syphilis, Mumps, and Pertussis data provisioning.
  - The MMGs are expected to be delivered by the SOT to the MVPS Team on 8/6/15.
  - The MVPS team will develop the message processing guides (MPGs) and also work on the data provisioning requirements in conjunction with the SOT and M&V Teams.
- The MVPS Team is supporting the development of the Arboviral and Varicella MMGs by participating in the MMG Lifecycle activities.

### Technical Assistance Updates

- **Update on Jurisdiction Implementation:** Note that now we are including updates on all pilot jurisdictions involved in NMI, both National Electronic Disease Surveillance System Base System

(NBS) and non-NBS jurisdictions. The NBS Team provides technical assistance (TA) for NBS pilot jurisdictions, and the APHL TA Team provides technical assistance for non-NBS pilot jurisdictions.

- **Alabama:**
  - Alabama implemented the patch release for Beta 2 of the NBS 4.6 release that CDC provided on 7/27/15.
  - Currently, the state is testing STD messages by using the Message Evaluation and Testing Service (METS) tool and migrating STD data.
- **Arkansas:**
  - Arkansas implemented the patch release for Beta 2 of the NBS 4.6 release that CDC provided on 7/27/15.
  - All of the state's Hepatitis test scenario notifications passed the METS tool without errors after updating the test messages to account for METS known issues. Currently, the state is testing Generic v2 test messages by using the METS tool.
  - Currently, the state is testing Generic v2 test messages by using the METS tool.
- **California:**
  - The APHL TA Team is currently customizing the Rhapsody route for California that will create HL7 messages based on their data extract for STD and Hepatitis.
- **Florida:**
  - Florida has created initial HL7 test messages for Hepatitis and is currently developing STD test messages.
  - The APHL TA Team will review and provide feedback on test messages as they are created.
- **Idaho:**
  - Idaho implemented the patch release for Beta 2 of the NBS 4.6 release that CDC provided on 7/27/15.
  - The state plans to start testing STD messages by using the METS tool the week of 8/10/15.
- **Kentucky:**
  - Kentucky implemented the patch release for Beta 2 of the NBS 4.6 release that CDC provided on 7/27/15.
  - The state is testing Hepatitis messages by using the METS tool.
- **Louisiana:**
  - Louisiana implemented the patch release for Beta 2 of the NBS 4.6 release that CDC provided on 7/27/15.
  - The state is testing Hepatitis messages by using the METS tool.
- **Michigan:**
  - Michigan attended an MVPS Dashboard and UAT training session on 8/3/15.
  - Michigan completed the full suite of test messages for Hepatitis and STD and is ready for independent validation.
- **Minnesota:**
  - The APHL TA Team is reviewing and providing feedback on the data extract for STD and Hepatitis that will be used to customize the Rhapsody route for Minnesota.
- **Oregon:**

- Oregon attended an MVPS Dashboard and UAT training session on 8/3/15.
    - Oregon created HL7 test messages for Hepatitis and is building the full suite of messages for STD.
    - The APHL TA Team will review and provide feedback on test messages as they are created.
  - **Tennessee:**
    - Tennessee implemented the patch release for Beta 2 of the NBS 4.6 release that CDC provided on 7/27/15.
    - The state is testing the base Hepatitis page and porting the legacy data to the new template.
  - **Texas:**
    - Texas implemented the patch release for Beta 2 of the NBS 4.6 release that CDC provided on 7/27/15.
    - The state plans to start testing Hepatitis messages by using the METS tool the week of 8/10/15.
- CSTE will work with all of the pilot jurisdictions to evaluate the NMI TA efforts.
- Reminder about MMG status:
  - MMGs in Stages I and II are considered draft and may be revised until the time they are finalized.
  - Those jurisdictions selected for pilot testing of the test-ready versions (Stage II) of the MMGs should wait until contacted by the NMI TA Team before using the test-ready MMGs, before implementing surveillance information system changes, and before submitting test messages to CDC.
  - All other jurisdictions should not plan to submit data to CDC or implement MMG-based updates to their surveillance information systems until the final MMGs (Stage III) have been posted.
- For more information about technical assistance:
  - Please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>.
  - For pilot jurisdictions: If you have questions specific to NMI TA, please contact Laura Carlton, APHL, at [laura.carlton@aphl.org](mailto:laura.carlton@aphl.org).
  - For non-pilot jurisdictions: If you have questions or would like to request TA through the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Cooperative Agreement, please email [edx@cdc.gov](mailto:edx@cdc.gov).

*For more information on NMI, please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>. If you have questions not answered in the FAQs, please send them to [edx@cdc.gov](mailto:edx@cdc.gov).*